Teleflex Incorporated (NYSE:TFX) Receives Consensus Rating of “Hold” from Analysts

Shares of Teleflex Incorporated (NYSE:TFX) have earned a consensus rating of “Hold” from the eleven brokerages that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, eight have given a hold rating and two have given a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $164.63.

Several research analysts have weighed in on TFX shares. Truist Financial decreased their price target on shares of Teleflex from $140.00 to $137.00 and set a “hold” rating on the stock in a research report on Monday, May 5th. Morgan Stanley decreased their price objective on shares of Teleflex from $191.00 to $173.00 and set an “overweight” rating on the stock in a research report on Monday, May 5th. Wall Street Zen downgraded shares of Teleflex from a “buy” rating to a “hold” rating in a research report on Friday, February 28th. Raymond James downgraded shares of Teleflex from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Finally, Bank of America downgraded shares of Teleflex from a “neutral” rating to an “underperform” rating and decreased their price objective for the company from $235.00 to $140.00 in a research report on Tuesday, March 4th.

Teleflex Stock Up 0.0%

TFX opened at $120.95 on Friday. The company has a current ratio of 2.42, a quick ratio of 1.39 and a debt-to-equity ratio of 0.37. Teleflex has a 1-year low of $119.08 and a 1-year high of $249.91. The company has a market capitalization of $5.34 billion, a PE ratio of 24.05, a PEG ratio of 1.73 and a beta of 1.17. The firm’s 50 day simple moving average is $131.43 and its two-hundred day simple moving average is $160.11.

Teleflex (NYSE:TFX) last released its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.91 earnings per share for the quarter, topping the consensus estimate of $2.88 by $0.03. Teleflex had a net margin of 7.85% and a return on equity of 14.19%. The business had revenue of $700.67 million for the quarter, compared to the consensus estimate of $699.37 million. During the same period last year, the firm earned $3.21 earnings per share. The company’s quarterly revenue was down 5.0% on a year-over-year basis. As a group, equities analysts forecast that Teleflex will post 13.98 EPS for the current year.

Teleflex Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, June 16th. Shareholders of record on Tuesday, May 20th will be issued a $0.34 dividend. The ex-dividend date is Tuesday, May 20th. This represents a $1.36 dividend on an annualized basis and a yield of 1.12%. Teleflex’s dividend payout ratio is currently 42.90%.

Institutional Trading of Teleflex

A number of institutional investors and hedge funds have recently bought and sold shares of TFX. MassMutual Private Wealth & Trust FSB increased its holdings in Teleflex by 103.1% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 197 shares of the medical technology company’s stock valued at $27,000 after acquiring an additional 100 shares during the last quarter. Banque Cantonale Vaudoise bought a new stake in Teleflex in the 1st quarter valued at $27,000. Costello Asset Management INC bought a new stake in Teleflex in the 1st quarter valued at $28,000. Headlands Technologies LLC bought a new stake in Teleflex in the 4th quarter valued at $29,000. Finally, Brooklyn Investment Group increased its holdings in Teleflex by 258.6% in the 1st quarter. Brooklyn Investment Group now owns 208 shares of the medical technology company’s stock valued at $29,000 after acquiring an additional 150 shares during the last quarter. 95.62% of the stock is currently owned by institutional investors.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.